Inside This Issue: Hearing Disorders
Top News Alerts: Product Updates, Deals & Financings
Featured Topic: The Future of Neuroscience Research Congressional Hearing
Company Spotlight: Microtransponder
Subscribe now to access over 30 articles covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Highlights: How to Answer the Big Questions about the Brain
Big questions in neuroscience were tackled this month from Seattle to DC. The Allen Institute for Brain Science hosted the first of what they plan to be an annual Symposium “Open Questions in Neuroscience.” Microsoft co-founder Paul Allen has so far invested $126 million into the Institute, launched in 2003, which has created publicly available brain genome atlases. Allen also makes investments through Vulcan Capital, which gave Omeros, focused on inflammation and CNS disorders, a $20 million boost this month (see story, page 15)...
Loud and Clear Demand for Hearing Disorder Treatments
The incidence of hearing loss and other hearing disorders like tinnitus is increasing rapidly and currently affects over 30% of the general population in the US. Hearing loss is progressive with age and can be made worse by loud sounds, certain drugs, infections, and other hereditary and nonhereditary factors. While no drugs for protection or restoration of hearing currently exist, there are a number of devices already in use and pharmaceuticals in development. This article outlines hearing disorders, current treatments and drug, gene and device therapies in development ...
MicroTransponder: Small Device, Big Possibilities
Microtransponder is a small private company focused on wireless neurostimulation devices hailing from Dallas, Texas. It is headed up by Will Rosellini, a Texas native and former pro baseball player with the Arizona Diamondbacks. Rosellini earned a law degree and seven master's degrees since he retired in 2001. He is currently pursuing a PhD in neuroscience in the lab of company founder Larry Cauller, who developed the neurostimulation technology as an associate professor at University of Texas, Dallas. NeuroInsights spoke with Rosellini and asked how the company got started...
Companies Covered In This Issue Include: Neurologix, Shionogi, Addrenex, Zarlink, CVRx, Johnson & Johnson, Sun Pharmaceutical, Sanofi-Aventis, Targacept, Allon, Abbott, Boehringer Ingelheim, Merck Serono, Jazz Pharma, AstraZeneca, Accera, Genentech, Biogen Idec, Questcor, GE Healthcare, Eyetech, Alkermes, Xenoport, BrainStorm CEll Therapeutics, Pfizer, Alexza Pharmaceuticals, Neurotune, Eisai, Arena, Intellect Neurosciences, Neovista, Transcept, Brainsway, Adolor, Allergan, Nektar, Verona Pharma, StemCells, Avanir, NeuroRepair, Convergence Pharma, Moksha8, Medtronic, Banyan Biomarkers, Dormir, Neuronex, Cortex, Nautilus Neuro, Posit Science, Cypress, Exagen, Takeda, Envoy, GlaxoSmithKline, Omeros, Dakim, NeuroVive, Neurowave, Setpoint Medical, Lundbeck Genmab, Synosia, UCB, King Pharma, Agenebio, Mind-NRG, Astex, Jingxin, Stryker, Boston Scientific, Sound Pharmaceutics, GenVec, MicroTransponder, Novartis, Otonomy, Auris Medical, Merz Pharamceutials, Sonitus Medical, Cochlear Corp., Advanced Bionics, Sonova, Neuromonics, Med-El, Otologics, Envoy Medical
Subscribe Now:
|
|
